Best Selling Cocarboxylase CAS 154-87-0 Cocarboxylase Powder CAS NO.154-87-0

 What is Cocarboxylase

Tauroursodeoxycholic acid (TUDCA) is an ambiphilic bile acid. It is the taurine conjugate form of ursodeoxycholic acid (UDCA). Humans are found to have trace amounts of TUDCA. Ongoing research is finding TUDCA has diminishing apoptotic effects, with potential application in heart disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis and stroke. Recently, TUDCA has been found to have protective effects in the eye, especially concerning retinal degenerative disorders.

Function of Cocarboxylase
 

TUDCA has been found to have protective effects in the eye, especially concerning retinal degenerative disorders.

Application of Cocarboxylase

Tauroursodeoxycholic acid (TUDCA) is an ambiphilic bile acid. It is the taurine conjugate form of ursodeoxycholic acid (UDCA). Humans are found to have trace amounts of TUDCA. Ongoing research is finding TUDCA has diminishing apoptotic effects, with potential application in heart disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis and stroke. Recently, TUDCA has been found to have protective effects in the eye, especially concerning retinal degenerative disorders.

Vandetanib is a small molecule multi-target tyrosine kinase inhibitor developed by AstraZeneca. It was approved by the US FDA in April 2011 under the trade name of Zactima. This medicine is a tablet for the treatment of advanced medullary thyroid cancer in adult patients. Vandetanib is a multi-target tyrosine kinase inhibitor, belonging to the aniline quinazoline class of compounds, known as "second-generation Iressa", which not only acts on the EGFR, VEGFR and RET tyrosine kinases of tumor cells , but also inhibits other tyrosine kinases as well as serine/threonine kinases. Vandetanib is the first approved treatment for medullary thyroid cancer for the treatment of unresectable, locally advanced or metastatic symptomatic or progressive medullary thyroid cancer. Results of a randomized, placebo-controlled clinical trial showed that vandetanib significantly delayed the time to progression in locally advanced or metastatic medullary thyroid cancer. The recommended daily dose is 300 mg (oral), and treatment should be discontinued when the patient develops tolerance to the drug or cannot tolerate its toxicity. The most common adverse reactions to the drug were diarrhea, rash, acne, nausea, high blood pressure, headache, fatigue, decreased appetite, and abdominal pain. The incidence of adverse reactions is related to the dose. When <300mg/d, the patient tolerated it well, and the maximum tolerated dose (MTD) was 300mg. Phase II clinical studies involve many diseases. Clinical trials of vandetanib in the treatment of NSCLC are currently underway in my country. British AstraZeneca Pharmaceutical Co., Ltd. (AstraZeneca) obtained the world patent rights in May 2001 and October 2001 respectively (WO2001032651, WO2001074360), respectively, the structural formula of the compound, the synthesis method and the pharmaceutical composition (including the addition salt) ) and applied for corresponding protection. Vandetanib, which inhibits the development of medullary thyroid cancer, is the first FDA-approved drug to treat the disease and will help treat adult patients with advanced medullary thyroid cancer.

Q1.Are you a manufacturer or a trading company
A1.Our company is a leading manufacturer specializing in trade and the development, production and marketing of pharmaceutical intermediates and apis for more than 10 years.
Q2.What about the quality of your products
A2.We value quality as life.We strictly control the quality of each process, established a perfect quality control system.
Q3.In the third quarter.What is your minimum order quantity
A3.Our minimum order quantity is 1 gram.
Q4.Fourth quarter.Can you provide free test samples
A4.Yes, we can provide 10g free samples for consumer test.
Q5.What is your delivery time
A5.Delivery takes 2-3 days, depending on the destination.
Q6.What about the mode of transportation
A6.For urgent and light orders, UPS, FedEx, DHL, EMS can be used;For heavier goods, we provide the method of air or sea transportation to consumers.
Q7.So far.How about the terms of payment
A7.We accept T/T,  Paypal, , money gram, etc.
 

Wuhan Kanal Technology Co., Ltd. founded in 2010,it is a large manufacturer of fine Pharmaceutical& Chemical & Cosmetic materials that integrates R&D, production and sales together.  Our Kanal company is established under the support of the Wuhan city government, so Kanal has large advantages in enterprise credit, finance security, product quality control, and cargo export.Kanal locates in the national new materials industry park of Wuhan city and is awarded the title of high-tech corporation.

Wuhan Kanal has its own R&D and development laboratory. We Kanal set up a R&D team with rich experience and strong technical strength, most of the practitioners have more than ten years' experience and technology in organic synthesis development. It owns almost 15 acre and more than 280 workers.

An ISO 9001 & GMP qualified company, we are mainly specialized in producing high quality but low price Pharmaceutical intermediates, APIs and other fine chemicals & cosmetics products which related to human and animals medicines as well as additives in gas &oil field, almost half of the goods are for exporting. What's more, we provide the OEM (customize) manufactures, if you can't find materials from the world, then tell us, we will research and produce in our high-tech equipmented laboratory. We are dedicated to satisfying our customers with our products and services.


1. We has 11 years' exporting experience in active pharmaceutical ingredient products.
Our professional and thoughtful after-sales service eliminates your worries.

2.We can provide you with ten thousands of products of different levels.

3. We offer convenient one-station purchasing service.

(1)Any inquiries will be replied within 12 hours.
(2)Dedication to quality, supply & service.
(3)Strictly on selecting raw materials.
(4)Reasonable & competitive price, fast lead time.

Our company is based on the optical valley biological city,making full use of the park policy advantages, focusing on the research and development of biological medicine.

The pharmaceutical intermediates are mainly applied to anti-cancer, anti-depression, cardiovascular, diabetes and other new medicine. The chemical intermediates mainly refer to heterocyclics and OLED intermediates.Our factory produce new fine chemical materials which are mainly used in water treatment, bactericidal and anti-corrosion, dyes, electronic materials and other industry fields.
Wuhan Kanal has export & import license, and hazard chemical sales license. The products are exported to America, Brazil, South Korea, Japan, Taiwan, Malaysia, Thailand, Indonesia, Europe union and other countries or regions. 
Under rich experiences and excellent international reputation, the company becomes a quite influential enterprise in China's API field. Wuhan Kanal sincerely look forward to establishing long good cooperation with our customers from all over the world.